Key points are not available for this paper at this time.
Diwu Yanggan (DWYG) is a medicinal food formula that has demonstrated in vivo hepatoprotective properties. However, the mechanisms underlying DWYG's effects against hepatic precancerous lesions have not yet been elucidated. In this study, we aimed to investigate the potential role of DWYG in alleviating pre-cancerous liver lesions and explore the associated mechanisms using a rat model of 2-acetylaminofluorene/partial hepatectomy (2-AAF/PH) induced hepatic precancerous lesions. Our results demonstrated that treatment with Diwu Yanggan significantly reduced the levels of alanine transaminase (ALT) and aspartate transaminase (AST) in the liver compared to the model group. Additionally, alkaline phosphatase (ALP) levels approached those observed in the control group. Meanwhile, the expression of interleukin-6 (IL-6) and hepatocyte growth factor (HGF) was also decreased in the DWYG group. Collectively, our findings suggest that DWYG exhibits significant inhibitory effects on hepatic precancerous lesions in the 2-AAF/PH rat model through modulation of the IL-6/HGFsignaling system.
Xu et al. (Mon,) studied this question.